Cartesian Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Cartesian Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 3 currently recruiting 1 completed early-phase tilt top decile by trial count

Cartesian Therapeutics: 12 sponsored US clinical trials, 3 recruiting.

Cartesian Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Juvenile Myasthenia Gravis, with 1 trials.

Top-decile sponsor footprint

Cartesian Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 2

Descartes-08 in Autoantibody Myositis

NCT07391605
RECRUITING Phase 1

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

NCT07089121
RECRUITING Phase 3

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

NCT06799247
ACTIVE NOT RECRUITING Phase 2

Descartes-08 for Patients With Systemic Lupus Erythematosus

NCT06038474
ACTIVE NOT RECRUITING Phase 2

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

NCT04146051
TERMINATED Phase 1

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

NCT06304636
TERMINATED Phase 2

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

NCT04816526
TERMINATED Phase 1

Descartes-25 in Relapsed/Refractory Multiple Myeloma

NCT05113342
COMPLETED Phase 2

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

NCT04436029
TERMINATED Phase 1

Study of Descartes-30 in Acute Respiratory Distress Syndrome

NCT04524962
TERMINATED Phase 1

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

NCT03994705
TERMINATED Phase 1

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

NCT03448978

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 5
Phase 3 1

Therapeutic Areas

Juvenile Myasthenia Gravis 1
ANCA-Associated Vasculitis (AAV) 1
Childhood-onset Systemic Lupus Erythematous 1
Myasthenia Gravis, Generalized 1
Myasthaenia Gravis 1
Juvenile Dermatomyositis 1
Systemic Lupus Erythematosus (SLE) 1

What is open in the Cartesian Therapeutics pipeline

3 recruiting of 12 indexed (25% open); 1 completed (8%).

Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Juvenile Myasthenia Gravis (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cartesian Therapeutics: open-pipeline peers nationwide

Peers matched on 12 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Cartesian Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 2468101214 0%10%20%30% Total trials Recruiting share Cartesian TherapeuticsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAB ScienceAbbott Point of CareAbdul Latif Jameel Poverty Action LabAccutar Biotechnology
Cartesian Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cartesian Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cartesian Therapeutics page

12 registered trials is a research-attention snapshot, not an endorsement of Cartesian Therapeutics or any single study.

  • 3 of Cartesian Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Juvenile Myasthenia Gravis is the condition Cartesian Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Juvenile Myasthenia Gravis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cartesian Therapeutics pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.